Contact Us marketing@medicilon.com
Medicilon Logo
|
search icon search icon contact icon menu icon
Medicilon Logo
|
search icon close search icon contact icon menu icon
Message
Contact Us
Close Button
Back To Top
Online Message×
Click switch
Close Button

FAQs

FAQs
Preparation of Monoclonal Antibodies
(1) Hybridoma technology, including chimeric antibody preparation technology; (2) Screen library including phage antibody library technology and ribosome display technology; (3) Genetic mice preparation antibody technology (4) Single-cell screening technology;
Learn more
What are the Advantages and Disadvantages of Monoclonal Antibodies?
Advantage: High binding affinity; Prolonged Long duration of pharmacokinetic profile
Learn more
What is an in vitro ADME Study?
PPB(plasma protein-binding):3 concentrations (including effective concentrations),N=3, focusing on concentration dependence and species differences.
Learn more
What are Pharmacokinetic challenges of Biotech Drugs?
Species differences,analysis methods,basal concentrations,catabolism and elimination,antibody formation administration regimen,binding proteins,preparation quality,drug interactions
Learn more
What is Preclinical PK Analysis Method?
Noncompartmental Analysis (non-compartmental model); Traditional Compartmental PK Model;Population PK Model;
Learn more
Advantages and Disadvantages of Ligand Binding Assay
The Main Advantages of LBA:Sensitivity: High ; Quantitation: Cost effective and Fast The Main Disadvantage of LBA:Require good reagent (time) ;​Dilutions, nonlinear, matrix effect, hook effect, etc.
Learn more
How to Generate Bispecific Antibody?
The preparation of bispecific antibodies mainly includes methods such as hybridoma fusion, chemical conjugation, recombinant gene preparation, etc. Recombinant DNA technology is currently the most used technology for preparing BsAb.
Learn more
What are Bispecific Antibodies
Bispecific antibodies (BsAbs), also known as bifunctional antibodies, can simultaneously recognize and bind two different antigens and epitopes, thereby blocking two different signaling pathways to exert their effects.
Learn more
Why are Bispecific Antibodies Advantageous?
Killing tumors induced by mediated immune cells; Blocking dual target signal, exerting unique or repetitive functions, effectively preventing drug resistance; Greater specificity, targeting ability, and reduced off-target toxicity, effective reduction of treatment costs.
Learn more
Application of PDX Models
In particular, patient screening and predictive biomarker studies in clinical trials of tumor immune-targeted drugs show that PDX efficacy evaluation results and clinical similarity reached 87% (CDX only 5%).
Learn more